In a randomized controlled-trial study on 50 patients with chronic kidney disease stage II-IV, we found, allopurinol could ameliorate metabolic acidosis and glomerular filtration by reducing serum uric acid levels.
Introduction
Chronic kidney disease (CKD) is defined as chronic irreversible nephron damage either reduction in the number of nephrons or their function (1, 2) . CKD presents with reducing the renal function with or without azotaemia or kidney damage for more than three months (1, 2) . CKD is a global health issue which imposes high costs on nations (1) . The prevalence of CKD was reported to be 13.4% for all five stages and 10.6% for stage II to V (1) . CKD is associated with increased mortality mainly due to cardiovascular disease (CVD) and less importantly due to cancer (2) .
Increased serum uric acid levels are commonly seen in CKD patients (3) . For decades, increased serum uric acid was considered as a risk factor for CVD but recent epidemiological studies have shown that increased serum uric acid is associated with increased risk of hypertension, CKD, CVD and mortality (3, 4) . Hyperuricemia has been shown to be related to hypertension, proteinuria, renal function impairment and progressive nephropathy as well as CVD. Animal studies have shown that the mechanism of injury by hyperuricemia is through endothelial cell damage, activation of renin-angiotensin-aldosterone system and increased oxidative stress (5, 6) . Allopurinol is a xanthine oxidase inhibitor that inhibits the production of hypoxanthine from xanthine, a precursor of uric acid (7) . Few studies assessing the effects of allopurinol on renal function and metabolic acidosis have shown that allopurinol prevents the progression of renal failure, its complications (3, 8) and metabolic acidosis (9) .
Objectives
The aim of this study was to evaluate the effect of allopurinol administration on metabolic acidosis in CKD patients in Mashhad, Iran.
Patients and Methods

Study design
This randomized controlled trial was conducted on patients with CKD who referred to Qaem and Montaserieh hospitals, Mashhad, Iran. Subjects were selected based on convenient sampling (Patients randomly selected with double blinded method). Patients were included in the study if they were within the age range of 18 to 80 years, with the diagnosis CKD (stage II to IV), hyperuricemia (serum uric acid between 6 and 10 mg/dL) and metabolic acidosis (serum bicarbonate between 15 and 20 mg/ dL). Subjects were excluded if they had positive history of gout disease, myeloproliferative disease, or previous consumption of allopurinol or allergy to allopurinol. Patients were randomly allocated to either intervention group who received 100 mg/daily allopurinol or control group who received vitamin B1 as placebo in addition to conventional medications. The duration of intervention was three months. The Consort flow diagram of the study is presented in Figure 1 .
The demographic information were obtained from all patients at baseline. Measurements included serum uric acid level, bicarbonate level, creatinine and pH. Measurements were performed at baseline and at the end of the third month. Glomerular filtration rate (GFR) was calculated by CKD-EPI (chronic kidney disease epidemiology collaboration) equation formula. 
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Statistical analysis
Data were analyzed by the statistical package for social sciences (SPSS) version 22 (IBM Inc. Chicago, Il, USA). Continuous variables were checked for normality using the Shapiro-Wilk test and were presented as mean and standard deviation (SD). Categorical variables were presented as frequency and percentage. Comparison of continuous demographic variables between groups was performed by independent student t test while the chisquared test was used to compare the distribution pattern of categorical variables. The repeated measures analysis of covariance (ANCOVA), with diastolic blood pressure as covariate, was used to assess the group, time and time× group effects of intervention and to compare changes in study variables between and within the groups.
Results
Totally 50 subjects (25 in the allopurinol group and 25 in the control group) participated in this study. Table 1 shows that the majority of the subjects in the current study were male. The most common etiology for CKD in the whole cohort was diabetes mellitus (36.0%) followed by unknown cause (20.0%) and GN (16.0%) ( Table 1 ). The mean age of the subjects was 54.04±12.62 years. There was no significant difference in demographic characteristics between groups (P > 0.05) except for diastolic blood pressure (P = 0.002) ( Tables 1 and 2 ).
There were no significant differences in outcome between the two groups at baseline (P > 0.05) ( Table 3) . The ANCOVA revealed a significant effect (P < 0.05) for all variables except uric acid (P = 0.96) and significant time×group effect for all outcome (P < 0.05) ( Table 3) . Intervention resulted in a significant reduction in serum uric acid (P < 0.001), and a significant increase in serum bicarbonate, pH (P < 0.001 for each variable) and GFR (P = 0.002) in the allopurinol administered group. No significant difference was observed in serum creatinine between baseline and three months of intervention in allopurinol administered group (P = 0.10). Among the subjects in control group a significant reduction was observed in serum uric acid (P = 0.01) and GFR (P = 0.003), and also a significant rise in serum creatinine at three months versus baseline (P = 0.01) ( Table 3 ).
Discussion
This study showed that the mean age of CKD patients was 54.04 ± 12.62 years. This finding was in line with previous studies (10, 11) . On the other hand, the majority of the subjects in the current study were male which was in contrast to the higher reported prevalence of CKD among females. This difference might be due to small sample size of the current study, while our sample size was defined based on RCT design (10, 12) . Furthermore diabetes mellitus was the major underlying cause of CKD in the current study which was in line with the previous studies in the region (13, 14) .
The findings of this study revealed that inclusion of allopurinol in the treatment of CKD patients resulted in a significant increase in serum bicarbonate and PH. This effect was observed regardless of the increased GFR and reduced serum uric acid in both intervention and control group. This finding was similar to the findings of a previous study in which three months administration of allopurinol in 30 CKD patients in the stages II to IV resulted in improved endothelial function and acidosis (9, 15, 16) . Although the mechanism of allopurinol action is yet unknown, animal studies have demonstrated that uric acid reduction might result in improvement of blood pressure and proteinuria and therefore reduce the progression of CKD by reducing the production of reactive oxygen species (17) (18) (19) (20) .
This study also showed a significant increase in GFR in the intervention group and a significant decline in GFR in the control group. However, at the end of three months there was only a trend in higher GFR in the allopurinol treated versus the controls (P = 0.05). Although the difference was non-significant, however allopurinol administration was found to increase GFR more than placebo. This finding was in line with the findings of a previous study that reported a significant improvement in GFR and creatinine due to the administration of allopurinol (8) .
Conclusion
The findings of the current study revealed that allopurinol administration might result in reduced metabolic acidosis and GFR in CKD patients by reducing serum uric acid levels
Study limitations
This study did not assess the mechanism of action of allopurinol on reducing metabolic acidosis in CKD patients. Further studies are recommended. Another, limitation of this study was the assessment of few serum biomarkers of kidney function and other metabolic clues that might lead to the understanding the mechanism of allopurinol action in CKD.
Authors' contribution
MM and MH designed the study, observed accuracy and validity of the study. DG collected the data and follow the study. MM supervised the project. MM and BH wrote the paper. All authors edited and revised the final manuscript and accepted its publication.
Conflicts of interest
The authors declared no competing interests.
Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.
Funding/Support
Vice chancellor for research Mashhad University of Medical Sciences supported this study (Grant #950015). 
